Literature DB >> 21163253

Identification of cancer stem cell markers in human malignant mesothelioma cells.

Farhana Ishrat Ghani1, Hiroto Yamazaki, Satoshi Iwata, Toshihiro Okamoto, Keisuke Aoe, Kazunori Okabe, Yusuke Mimura, Nobukazu Fujimoto, Takumi Kishimoto, Taketo Yamada, C Wilson Xu, Chikao Morimoto.   

Abstract

Malignant mesothelioma (MM) is an aggressive and therapy-resistant neoplasm arising from the pleural mesothelial cells and usually associated with long-term asbestos exposure. Recent studies suggest that tumors contain cancer stem cells (CSCs) and their stem cell characteristics are thought to confer therapy-resistance. However, whether MM cell has any stem cell characteristics is not known. To understand the molecular basis of MM, we first performed serial transplantation of surgical samples into NOD/SCID mice and established new cell lines. Next, we performed marker analysis of the MM cell lines and found that many of them contain SP cells and expressed several putative CSC markers such as CD9, CD24, and CD26. Interestingly, expression of CD26 closely correlated with that of CD24 in some cases. Sorting and culture assay revealed that SP and CD24(+) cells proliferated by asymmetric cell division-like manner. In addition, CD9(+) and CD24(+) cells have higher potential to generate spheroid colony than negative cells in the stem cell medium. Moreover, these marker-positive cells have clear tendency to generate larger tumors in mouse transplantation assay. Taken together, our data suggest that SP, CD9, CD24, and CD26 are CSC markers of MM and could be used as novel therapeutic targets. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21163253     DOI: 10.1016/j.bbrc.2010.12.054

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  38 in total

Review 1.  Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.

Authors:  Roberto E Favoni; Antonio Daga; Paolo Malatesta; Tullio Florio
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  In vitro experimental models of mesothelioma revisited.

Authors:  Anand Singh; Nathanael Pruett; Chuong D Hoang
Journal:  Transl Lung Cancer Res       Date:  2017-06

3.  Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Authors:  Irina M Shapiro; Vihren N Kolev; Christian M Vidal; Yuwaraj Kadariya; Jennifer E Ring; Quentin Wright; David T Weaver; Craig Menges; Mahesh Padval; Andrea I McClatchey; Qunli Xu; Joseph R Testa; Jonathan A Pachter
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

Review 4.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

5.  Gene expression changes in human lung cells exposed to arsenic, chromium, nickel or vanadium indicate the first steps in cancer.

Authors:  Hailey A Clancy; Hong Sun; Lisa Passantino; Thomas Kluz; Alexandra Muñoz; Jiri Zavadil; Max Costa
Journal:  Metallomics       Date:  2012-06-19       Impact factor: 4.526

6.  Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy.

Authors:  Xu-Bin Deng; Li Xiao; Yue Wu; Fang Jin; Brooke Mossman; Joseph R Testa; Guang-Hui Xiao
Journal:  Int J Cancer       Date:  2014-12-27       Impact factor: 7.396

Review 7.  DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Authors:  Aline Beckenkamp; Samuel Davies; Júlia Biz Willig; Andréia Buffon
Journal:  Tumour Biol       Date:  2016-03-04

Review 8.  Interpretation of interlocking key issues of cancer stem cells in malignant solid tumors.

Authors:  Wei-Hui Liu; Nan You; Ning Zhang; Hong-Tao Yan; Tao Wang; Zhu Huang; Hong-Bao Liu; Li-Jun Tang
Journal:  Cell Oncol (Dordr)       Date:  2012-11-22       Impact factor: 6.730

9.  Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.

Authors:  Craig W Menges; Yuwaraj Kadariya; Deborah Altomare; Jacqueline Talarchek; Erin Neumann-Domer; Yue Wu; Guang-Hui Xiao; Irina M Shapiro; Vihren N Kolev; Jonathan A Pachter; Andres J Klein-Szanto; Joseph R Testa
Journal:  Cancer Res       Date:  2013-12-26       Impact factor: 12.701

10.  Suppression of CD26 inhibits growth and metastasis of pancreatic cancer.

Authors:  Chunxiang Ye; Xiuyun Tian; Guanjun Yue; Liang Yan; Xiaoya Guan; Shan Wang; Chunyi Hao
Journal:  Tumour Biol       Date:  2016-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.